Literature DB >> 25354111

Enzalutamide in metastatic prostate cancer before chemotherapy.

Tomasz M Beer, Bertrand Tombal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25354111     DOI： 10.1056/NEJMc1410239

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  57 in total

1.  Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.

Authors:  Naoki Terada; Shusuke Akamatsu; Yoshiyuki Okada; Hiromitsu Negoro; Takashi Kobayashi; Toshinari Yamasaki; Yoshiyuki Matsui; Takahiro Inoue; Tomomi Kamba; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2016-06-28       Impact factor: 3.402

Review 2.  Precision medicine for advanced prostate cancer.

Authors:  Stephanie A Mullane; Eliezer M Van Allen
Journal:  Curr Opin Urol       Date:  2016-05       Impact factor: 2.309

Review 3.  The roles of microRNAs in the progression of castration-resistant prostate cancer.

Authors:  Satoko Kojima; Yusuke Goto; Yukio Naya
Journal:  J Hum Genet       Date:  2016-06-09       Impact factor: 3.172

4.  Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

Authors:  Anuradha Jayaram; Gerhardt Attard
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

5.  Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Authors:  Yu-Ning Wong; Judith Manola; Gary R Hudes; Bruce J Roth; Judd W Moul; Andrea M Barsevick; Richard M Scher; Michael J Volk; David J Vaughn; Stephen D Williams; Michael J Fisch; David Cella; Michael A Carducci; George Wilding
Journal:  Clin Genitourin Cancer       Date:  2017-10-16       Impact factor: 2.872

Review 6.  [Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].

Authors:  K Miller; P Albers; R Eichenauer; G Geiges; M-O Grimm; F König; G Mickisch; D Pfister; C Schwentner; H Suttmann; S Zastrow
Journal:  Urologe A       Date:  2016-09       Impact factor: 0.639

Review 7.  Clinical and Novel Biomarkers in the Management of Prostate Cancer.

Authors:  Cristóbal Sanhueza; Manish Kohli
Journal:  Curr Treat Options Oncol       Date:  2018-02-08

8.  Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone.

Authors:  Charles J Ryan; Thian Kheoh; Jinhui Li; Arturo Molina; Peter De Porre; Joan Carles; Eleni Efstathiou; Philip W Kantoff; Peter F A Mulders; Fred Saad; Kim N Chi
Journal:  Clin Genitourin Cancer       Date:  2017-07-25       Impact factor: 2.872

Review 9.  Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.

Authors:  Yeung Ho; Scott M Dehm
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

10.  Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

Authors:  Bin Wang; U-Ging Lo; Kaijie Wu; Payal Kapur; Xiangyang Liu; Jun Huang; Wei Chen; Elizabeth Hernandez; John Santoyo; Shi-Hong Ma; Rey-Chen Pong; Dalin He; Yi-Qiang Cheng; Jer-Tsong Hsieh
Journal:  Int J Cancer       Date:  2017-07-31       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.